{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:06:26Z","timestamp":1792134386469,"version":"4.4.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neuropharm.2022.109305","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:57:32Z","timestamp":1667091452000},"page":"109305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Ketamine and its metabolites: Potential as novel treatments for depression"],"prefix":"10.1016","volume":"222","author":[{"given":"Kai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-8192","authenticated-orcid":false,"given":"Yitan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109305_bib1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41386-020-0644-9","article-title":"Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpsychires.2016.12.002","article-title":"Effects of ketamine administration on mTOR and reticulum stress signaling pathways in the brain after the infusion of rapamycin into prefrontal cortex","volume":"87","author":"Abelaira","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109305_bib3","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.4088\/JCP.17f11738","article-title":"Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency?","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109305_bib5","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1038\/s41467-020-20190-4","article-title":"The role of dissociation in ketamine's antidepressant effects","volume":"11","author":"Ballard","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2022.109305_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.111928","article-title":"Long-lasting effects of repeated ketamine administration in adult and adolescent rats","volume":"369","author":"Bates","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109305_bib7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1213\/ANE.0000000000001856","article-title":"In Vogue: ketamine for neuroprotection in acute neurologic injury","volume":"124","author":"Bell","year":"2017","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2022.109305_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib9","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib10","first-page":"503","article-title":"Antidepressants and suicidality","volume":"39","author":"Brent","year":"2016","journal-title":"Psychiatr. Clin."},{"key":"10.1016\/j.neuropharm.2022.109305_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.116.235838","article-title":"Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters","volume":"359","author":"Can","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109305_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.phrs.2018.02.007","article-title":"Neurobiological links between depression and AD: the role of TGF-\u03b21 signaling as a new pharmacological target","volume":"130","author":"Caraci","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2022.109305_bib13","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","article-title":"Antidepressant drugs act by directly binding to TRKB neurotrophin receptors","volume":"184","author":"Casarotto","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109305_bib14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/mp.2017.61","article-title":"Neuronal plasticity and neurotrophic factors in drug responses","volume":"22","author":"Castr\u00e9n","year":"2017","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109305_bib16","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/j.1464-410X.2008.07920.x","article-title":"The destruction of the lower urinary tract by ketamine abuse: a new syndrome?","volume":"102","author":"Chu","year":"2008","journal-title":"BJU Int."},{"key":"10.1016\/j.neuropharm.2022.109305_bib17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.bjp.0704315","article-title":"Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes","volume":"134","author":"Coates","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/BF00607095","article-title":"The binding of ketamine to plasma proteins: emphasis on human plasma","volume":"24","author":"Dayton","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib19","first-page":"Cd011611","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder","volume":"10","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2022.109305_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/02791072.2018.1506599","article-title":"The domino effect: Ed domino's early studies of psychoactive drugs","volume":"50","author":"Denomme","year":"2018","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2022.109305_bib21","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","article-title":"Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments","volume":"102","author":"Duman","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109305_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)01116-3","article-title":"Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord","volume":"333","author":"Ebert","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib25","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-020-0663-6","article-title":"Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression","volume":"45","author":"Farmer","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/exnr.1993.1153","article-title":"Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex","volume":"123","author":"Fix","year":"1993","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib27","first-page":"1517","article-title":"Depression is the leading cause of disability around the world","volume":"317","author":"Friedrich","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2022.109305_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00213-019-05346-5","article-title":"MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling","volume":"237","author":"Fujita","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109305_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109305_bib30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.neuropharm.2009.01.012","article-title":"Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1\/GluN2A) receptors","volume":"56","author":"Gilling","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.biopsych.2015.03.010","article-title":"Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia","volume":"77","author":"Gonzalez-Burgos","year":"2015","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","article-title":"Ketamine metabolite pilot study in a suicidal depression trial","volume":"117","author":"Grunebaum","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109305_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/mp.2015.211","article-title":"Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation","volume":"21","author":"Harraz","year":"2016","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib36","doi-asserted-by":"crossref","first-page":"11200","DOI":"10.1073\/pnas.2001264117","article-title":"Are NMDA and opioid receptors involved in the antidepressant actions of ketamine?","volume":"117","author":"Hashimoto","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109305_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01587-7","article-title":"Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic?","author":"Hashimoto","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys","volume":"267","author":"Hashimoto","year":"2017","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib39","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1176\/ajp.150.6.935","article-title":"Mental disorders and comorbidity in suicide","volume":"150","author":"Henriksson","year":"1993","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/dmd.30.7.853","article-title":"Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes","volume":"30","author":"Hijazi","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2022.109305_bib41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","article-title":"Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells","volume":"90","author":"Hirota","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib42","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/00000539-200212000-00025","article-title":"Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in Chinese hamster ovary cells","volume":"95","author":"Hirota","year":"2002","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2022.109305_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: at the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib44","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","article-title":"Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors","volume":"77","author":"Hustveit","year":"1995","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09540261.2020.1854194","article-title":"Ketamine for depression","volume":"33","author":"Jelen","year":"2021","journal-title":"Int. Rev. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neulet.2018.02.051","article-title":"Ketamine-induced neurotoxicity blocked by N-Methyl-d-aspartate is mediated through activation of PKC\/ERK pathway in developing hippocampal neurons","volume":"673","author":"Jiang","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2022.109305_bib48","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1038\/npp.2014.123","article-title":"The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression","volume":"39","author":"Jim\u00e9nez-S\u00e1nchez","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib49","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.3402\/ehtj.v4i0.7107","article-title":"The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use","volume":"4","author":"Kalsi","year":"2011","journal-title":"Emerg. Health Threats J."},{"key":"10.1016\/j.neuropharm.2022.109305_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bja.2021.02.034","article-title":"Stereoselective ketamine effect on cardiac output: a population pharmacokinetic\/pharmacodynamic modelling study in healthy volunteers","volume":"127","author":"Kamp","year":"2021","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2022.109305_bib51","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/nm.2886","article-title":"Decreased expression of synapse-related genes and loss of synapses in major depressive disorder","volume":"18","author":"Kang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2022.109305_bib52","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.mp.4001093","article-title":"NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia","volume":"7","author":"Kapur","year":"2002","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib53","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.3390\/nu13114158","article-title":"Ketamine as a treatment for anorexia nervosa: a narrative review","volume":"13","author":"Keeler","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.neuropharm.2022.109305_bib54","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2022.109305_bib55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbr.2015.03.023","article-title":"NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism","volume":"287","author":"Kiselycznyk","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109305_bib56","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109305_bib57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the potential of psychedelics for the treatment of PTSD","volume":"23","author":"Krediet","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib59","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib60","article-title":"BDNF release is required for the behavioral actions of ketamine","volume":"18","author":"Lepack","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib61","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109305_bib62","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/acps.12572","article-title":"Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression","volume":"134","author":"Loo","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2022.109305_bib65","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1113\/jphysiol.1991.sp018396","article-title":"Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones","volume":"432","author":"MacDonald","year":"1991","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib66","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib67","series-title":"A Review of the Current Literature","article-title":"Therapeutic potentials of ketamine and esketamine in obsessive-compulsive disorder (OCD), substance use disorders (SUD) and Eating disorders","volume":"vol. 11","author":"Martinotti","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109305_bib68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0304-3959(94)00170-J","article-title":"Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain","volume":"61","author":"Mathisen","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2022.109305_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1150516","article-title":"The antidepressant fluoxetine restores plasticity in the adult visual cortex","volume":"320","author":"Maya Vetencourt","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109305_bib70","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0022-3565(24)37943-1","article-title":"Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block","volume":"288","author":"Mealing","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109305_bib71","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejphar.2012.11.023","article-title":"Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in \u03b17 nicotinic acetylcholine receptors","volume":"698","author":"Moaddel","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib72","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1360-0443.2009.02761.x","article-title":"Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study","volume":"105","author":"Morgan","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2022.109305_bib74","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jad.2018.02.049","article-title":"Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression","volume":"232","author":"Niciu","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109305_bib75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3940(99)00688-6","article-title":"Ketamine stereoselectively inhibits rat dopamine transporter","volume":"274","author":"Nishimura","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2022.109305_bib76","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1523\/JNEUROSCI.4998-12.2013","article-title":"Acute suppression of spontaneous neurotransmission drives synaptic potentiation","volume":"33","author":"Nosyreva","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib77","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1126\/science.2660263","article-title":"Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs","volume":"244","author":"Olney","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109305_bib78","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1126\/science.1835799","article-title":"NMDA antagonist neurotoxicity: mechanisms and prevention","volume":"254","author":"Olney","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109305_bib79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn3504","article-title":"NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease","volume":"14","author":"Paoletti","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib80","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coph.2006.08.011","article-title":"NMDA receptor subunits: function and pharmacology","volume":"7","author":"Paoletti","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib81","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1016\/j.chroma.2010.06.028","article-title":"Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro","volume":"1217","author":"Portmann","year":"2010","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.neuropharm.2022.109305_bib82","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.neuron.2021.05.002","article-title":"Ventral pallidum DRD3 potentiates a pallido-habenular circuit driving accumbal dopamine release and cocaine seeking","volume":"109","author":"Pribiag","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109305_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16060-7","article-title":"Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model","volume":"7","author":"Qu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109305_bib84","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/ALN.0000000000001392","article-title":"Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance","volume":"125","author":"Rao","year":"2016","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib85","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1038\/s41467-022-30386-5","article-title":"Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice","volume":"13","author":"Rawat","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2022.109305_bib86","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.neuron.2018.05.018","article-title":"Glutamatergic signaling in the central nervous system: ionotropic and metabotropic receptors in concert","volume":"98","author":"Reiner","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109305_bib87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-clinpsy-072120-014126","article-title":"Ketamine and the future of rapid-acting antidepressants","volume":"17","author":"Riggs","year":"2021","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib88","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/npp.2016.224","article-title":"Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study","volume":"42","author":"Sanacora","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib89","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neuropharm.2014.07.008","article-title":"Enhancing ketamine translational pharmacology via receptor occupancy normalization","volume":"86","author":"Shaffer","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib90","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.urology.2007.01.038","article-title":"Ketamine-associated ulcerative cystitis: a new clinical entity","volume":"69","author":"Shahani","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.brainresbull.2018.10.004","article-title":"Essential roles of neuropeptide VGF regulated TrkB\/mTOR\/BICC1 signaling and phosphorylation of AMPA receptor subunit GluA1 in the rapid antidepressant-like actions of ketamine in mice","volume":"143","author":"Shen","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.109305_bib92","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1523\/JNEUROSCI.22-08-03251.2002","article-title":"Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression","volume":"22","author":"Shirayama","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00406-016-0718-1","article-title":"Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression","volume":"267","author":"Shirayama","year":"2017","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib94","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ijnp\/pyx108","article-title":"Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine","volume":"21","author":"Shirayama","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib95","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib96","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04993-7","article-title":"Dual action of ketamine confines addiction liability","volume":"608","author":"Simmler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109305_bib97","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib98","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/nau.24763","article-title":"Rodent models of ketamine-induced cystitis","volume":"40","author":"Sultana","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.neuropharm.2022.109305_bib99","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/jemt.21014","article-title":"Ketamine effects on the urogenital system--changes in the urinary bladder and sperm motility","volume":"74","author":"Tan","year":"2011","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.neuropharm.2022.109305_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172839","article-title":"Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: role of BDNF-TrkB signaling","volume":"188","author":"Tan","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109305_bib101","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4088\/JCP.v66n0803","article-title":"Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials","volume":"66","author":"Thase","year":"2005","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib102","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pbb.2018.07.003","article-title":"Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine","volume":"172","author":"Tian","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109305_bib103","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jpba.2017.09.033","article-title":"A rapid and sensitive chiral LC-MS\/MS method for the determination of ketamine and norketamine in mouse plasma, brain and cerebrospinal fluid applicable to the stereoselective pharmacokinetic study of ketamine","volume":"148","author":"Toki","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.neuropharm.2022.109305_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205002","article-title":"TGF-\u0392 signaling in cellular senescence and aging-related pathology","volume":"20","author":"Tominaga","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109305_bib105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109305_bib106","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib108","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109305_bib109","doi-asserted-by":"crossref","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104762","article-title":"(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: beyond depression","volume":"139","author":"Wang","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109305_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172870","article-title":"A historical review of antidepressant effects of ketamine and its enantiomers","volume":"190","author":"Wei","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109305_bib112","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euroneuro.2021.04.010","article-title":"Intranasal administration of transforming growth factor-\u03b21 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: a role of TrkB signaling","volume":"50","author":"Wei","year":"2021","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109305_bib113","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib114","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00000542-198003000-00008","article-title":"Pharmacology of ketamine isomers in surgical patients","volume":"52","author":"White","year":"1980","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/bja\/57.2.197","article-title":"Comparative pharmacology of the ketamine isomers. Studies in volunteers","volume":"57","author":"White","year":"1985","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2022.109305_bib117","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib118","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib119","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1464-410X.2012.11028.x","article-title":"The prevalence and natural history of urinary symptoms among recreational ketamine users","volume":"110","author":"Winstock","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.neuropharm.2022.109305_bib120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/0004867419883341","article-title":"Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials","volume":"54","author":"Witt","year":"2020","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib121","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00023210-200620030-00003","article-title":"Ketamine: from medicine to misuse","volume":"20","author":"Wolff","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2022.109305_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107710","article-title":"Potential link between antidepressant-like effects of ketamine and promotion of adult neurogenesis in the ventral hippocampus of mice","volume":"158","author":"Yamada","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib123","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","article-title":"(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice","volume":"43","author":"Yamaguchi","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib124","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/00000542-200004000-00033","article-title":"Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine","volume":"92","author":"Yamakura","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib125","doi-asserted-by":"crossref","first-page":"pyw080","DOI":"10.1093\/ijnp\/pyw080","article-title":"Antidepressant effects of (+)-MK-801 and (-)-MK-801 in the social defeat stress model","volume":"19","author":"Yang","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib126","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.biopsych.2018.05.007","article-title":"AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine","volume":"84","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib127","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib128","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib129","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109305_bib130","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib131","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109305_bib132","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109305_bib133","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib134","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","article-title":"A double-blind, placebo-controlled study of memantine in the treatment of major depression","volume":"163","author":"Zarate","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109305_bib135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109305_bib136","first-page":"pyu077","article-title":"Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation","volume":"18","author":"Zhang","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib137","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2174\/1570159X14666160119094646","article-title":"Brain-derived neurotrophic factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets","volume":"14","author":"Zhang","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109219","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109305_bib139","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","article-title":"An update on ketamine and its two enantiomers as rapid-acting antidepressants","volume":"19","author":"Zhang","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2022.109305_bib140","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang","year":"2019","journal-title":"Biol psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109305_bib141","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41598-018-22449-9","article-title":"Lack of metabolism in (R)-ketamine\u2019s antidepressant actions in a chronic social defeat stress model","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109305_bib142","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00406-019-01092-z","article-title":"Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effect of (R)-ketamine","volume":"271","author":"Zhang","year":"2019","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109305_bib143","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00213-018-5017-2","article-title":"Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model","volume":"235","author":"Zhang","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109305_bib144","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41398-020-0733-x","article-title":"Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109305_bib145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-021-03769-9","article-title":"Structural basis of ketamine action on human NMDA receptors","volume":"596","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109305_bib146","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-2125.2012.04198.x","article-title":"Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression","volume":"74","author":"Zhao","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109305_bib147","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:21:23Z","timestamp":1758439283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":145,"alternative-id":["S0028390822003641"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109305","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine and its metabolites: Potential as novel treatments for depression","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109305"}}